Holen Sie sich die Stockscreener-App
15.10
4.93%
0.71
Schlusskurs vom Vortag:
$14.39
Offen:
$14.53
24-Stunden-Volumen:
480.04K
Relative Volume:
1.07
Marktkapitalisierung:
$1.14B
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-10.00
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+5.15%
1M Leistung:
+5.45%
6M Leistung:
+4.93%
1J Leistung:
+35.30%
1-Tages-Spanne:
$14.53
$15.38
1-Wochen-Bereich:
$13.48
$15.38
52-Wochen-Spanne:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
15.10 | 1.06B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Implied Analyst Target Price of $70.96 for iShares Morningstar Small-Cap ETF (ISCB) Suggests 16% Gain Potential. - AInvest
Zymeworks to Engage in Key Investor Conferences - TipRanks
Zymeworks to Participate in Upcoming Investor Conferences. - AInvest
Zymeworks' Strategic Momentum in 2025: A High-Conviction Biotech Play in the ADC and Bispecific Antibody Space - AInvest
Zymeworks Inc. to Participate in Multiple Upcoming Investor Conferences in September 2025 - Quiver Quantitative
Zymeworks to Present at Several Upcoming Investor Conferences - AInvest
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Biotech Zymeworks Lines Up 4 Major Wall Street Healthcare Conference Presentations in September - Stock Titan
RSI Crosses Above 30 for Zymeworks Inc. — Reversal in SightPortfolio Value Report & Weekly Watchlist of Top Performers - 선데이타임즈
Short Interest Drops in Zymeworks Inc. After RallyMarket Growth Review & Fast Moving Market Watchlists - newsimpact.co.kr
Is Zymeworks Inc. stock forming a triangle patternJuly 2025 Action & AI Forecast Swing Trade Picks - sundaytimes.kr
What is the cash position of Zymeworks Inc.2025 Winners & Losers & Weekly Momentum Stock Picks - mustnews.co.kr
Zymeworks Inc. Revenue Forecasts Upgraded by 44%: Analysts See Substantial Growth Ahead - AInvest
Growth Investors: Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 44% - Yahoo Finance
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - Caledon Enterprise
Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression - MSN
Will Breakout in Zymeworks Inc. Sustain Through Next WeekJuly 2025 Drop Watch & Free Technical Pattern Based Buy Signals - beatles.ru
Screener Results Flag Zymeworks Inc. as OversoldTrade Risk Assessment & Free Reliable Trade Execution Plans - thegnnews.com
Short Term Charts Align With Long Term Uptrend in Zymeworks Inc.July 2025 Review & Long-Term Capital Growth Strategies - sundaytimes.kr
Zymeworks Inc. Added to Custom Quant Screener Today2025 Buyback Activity & Free Fast Entry Momentum Trade Alerts - thegnnews.com
Zymeworks (ZYME) Is Up 12.3% After Board Shakeup, Insider Investment, and Return to Profitability – Has The Bull Case Changed? - simplywall.st
Zymeworks (NASDAQ:ZYME) Issues Earnings Results - MarketBeat
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Ariva
Zymeworks Strengthens Leadership with New Board Appointments - TipRanks
Zymeworks Expands Board with Financial Veterans Greg Ciongoli and Robert E. Landry - The Indian Awaaz
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry | ZYME Stock News - GuruFocus
Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors - Quiver Quantitative
Zymeworks appoints two new directors to strengthen board By Investing.com - Investing.com Canada
Zymeworks appoints two new directors to strengthen board - Investing.com India
Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan
Will breakout in Zymeworks Inc. lead to full recoveryFree Breakout Entry Signal Confirmation Tool - Newser
Has Zymeworks Inc. formed a bullish divergenceLow Risk Stock Selection Strategy Guide - Newser
Zymeworks Inc. stock trendline breakdownFree Scalable Portfolio Growth Suggestions - Newser
Zymeworks Inc. stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser
Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - simplywall.st
Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Is Zymeworks Inc. forming a breakout patternDouble Capital Strategy Picks - thegnnews.com
Can Zymeworks Inc. hit a new high this monthFree Proven Entry Plan With Low Risk Trade - Newser
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Applying sector rotation models to Zymeworks Inc.Technical Reversal Setup with Risk Limits - Newser
What does recent volatility data suggest for Zymeworks Inc.Stock Price Prediction Using AI Tools - Newser
Why Zymeworks Inc. stock attracts strong analyst attentionFree High Yield Stocks With Buy Confirmation - Newser
Is Zymeworks Inc. affected by consumer sentimentStock Picks with 300% Gain - sisaissue.com
Zymeworks Q2 2025 Earnings Call: Capitalizing on Platform-Driven Innovation and Strategic Execution - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Purchases 4,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (NASDAQ:ZYME) Lowered to “Hold” Rating by Wall Street Zen - Defense World
Zymeworks Reports Strong Q2 2025 Financial Performance - The Globe and Mail
Zymeworks Reports Q2 Results and FDA Clearance - The Globe and Mail
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zymeworks Inc.-Aktie (ZYME) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
May 19 '25 |
Buy |
11.78 |
5,919 |
69,738 |
17,883,908 |
| EcoR1 Capital, LLC | Director |
Apr 16 '25 |
Buy |
11.16 |
73,953 |
825,589 |
17,773,727 |
| EcoR1 Capital, LLC | Director |
Apr 17 '25 |
Buy |
11.52 |
54,760 |
630,819 |
17,828,487 |
| EcoR1 Capital, LLC | Director |
Apr 04 '25 |
Buy |
11.17 |
196,438 |
2,193,800 |
17,699,774 |
| EcoR1 Capital, LLC | Director |
Apr 03 '25 |
Buy |
11.84 |
120,770 |
1,430,170 |
17,503,336 |
| EcoR1 Capital, LLC | Director |
Apr 02 '25 |
Buy |
11.85 |
74,360 |
881,017 |
17,382,566 |
| EcoR1 Capital, LLC | Director |
Apr 01 '25 |
Buy |
11.60 |
48,658 |
564,647 |
17,308,206 |
| EcoR1 Capital, LLC | Director |
Mar 31 '25 |
Buy |
11.75 |
4,397 |
51,658 |
17,259,548 |
| EcoR1 Capital, LLC | Director |
Mar 25 '25 |
Buy |
12.91 |
53,501 |
690,452 |
17,211,303 |
| EcoR1 Capital, LLC | Director |
Mar 26 '25 |
Buy |
12.24 |
43,848 |
536,857 |
17,255,151 |
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):